Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

zyme produced at the 2000L capacity and the timing thereof; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD, the timetables therefore and the impact of such approvals on the company; its plans and estimated timetables for new and next- generation product filings, regulatory actions and launches, including for Mozobil, Clolar, alemtuzumab-MS, mipomersen, Genz-112638 and Synvisc-ONE and the assessment of the market potential of such products; its projected Myozyme revenues for 2008; and its anticipated growth drivers for certain products and businesses, including Genetics and Thymoglobulin. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil, Clolar, alemtuzumab-MS, mipomersen, and Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Renvela and Synvisc-ONE; Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including Myozyme produced at the 2000L scale in the US and at the 4000L scale in Europe and the timing of receipt of such approvals; Genzyme's ability to manufacture its products, including Thymoglobulin and its LSD therapies in a timely and cost effective manner and in sufficient quantities to meet demand; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10-K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is pleased ... present a session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & ... largest analytical and scientific instruments show which will be held at International Conference ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience technology company ... system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional and ... performance. Vision is the inception of every move ... or blocking a pass. The critical impact vision speed has ...
Breaking Biology Technology:U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... CareFusion announced today that it has received 510(k) ... for its new electrodiagnostic system, known as the Viking ... device for monitoring and testing electrophysiological information from the ... http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) The new EDX ...
... 2012 /PRNewswire/ -- Jennerex, Inc., a ... and commercialization of first-in-class targeted oncolytic virus products ... has been treated in a Phase 1/2 clinical ... cancer who have become refractory to chemotherapy and ...
... 19, 2012 In recognition of her ongoing support ... Bailey Hutchison is the 2012 recipient of the National ... The senior senator from Texas was honored today during ... Facility that NSBRI shares with Baylor College of Medicine,s ...
Cached Biology Technology:CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System 2Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 2Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 3Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 4Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 5Space Research Institute Honors Senator Hutchison with Pioneer Award 2Space Research Institute Honors Senator Hutchison with Pioneer Award 3
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... will present techniques and discuss surgical approaches and applications ... Association of Neurological Surgeons (AANS), held April 9-13, 2011 ... The Department of Neurosurgery at NYU Langone Medical Center ... hospitals in the country for neurology and neurosurgery by ...
... A study of the salamander brain has led researchers ... hitherto unknown function of the neurotransmitter dopamine. In an article ... they show how in acting as a kind of ... neurons in the adult brain. Their findings may one day ...
... the Easter holiday season coming up soon, egg consumption is expected ... the maximum number of eggs they can? "Parasites such as ... five percent or more," says Bradley A. Mullens , a ... "One way to boost egg production is to rid the ...
Cached Biology News:NYU Langone experts present advances at American Association of Neurological Surgeons Meeting 2Dopamine controls formation of new brain cells 2UC Riverside entomologists propose pesticide-free method to increase egg production 2
... Eastman Kodak Companys Molecular Imaging Systems ... Image Station 4000 Digital Imaging Systems, ... technology for comprehensive fluorescence, luminescence, radiographic ... 4 million pixel CCD and 10x ...
... The RapidVUE is a particle shape and size ... been designed with the utmost simplicity in mind. ... delivery module and an optical bench. The system ... for easy upgrade for different applications such as ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential Neurological liabilities of compound...
Biology Products: